Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1

Status

Recruiting 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Lymphoma, Large B-Cell, Diffuse 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Burkitt Lymphoma 5Prostatic Neoplasms 4Neoplasms 4Leukemia, Biphenotypic, Acute 4Ovarian Neoplasms 3Lymphoma, Follicular 3Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Metastatic Castration-resistant Prostate Cancer 2Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell 2Hodgkin Disease 2Endometrial Neoplasms 2Down Syndrome 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Myasthenia Gravis 1Lymphoma, T-Cell, Peripheral 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Immunoblastic Lymphadenopathy 1Enteropathy-Associated T-Cell Lymphoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Bulbo-Spinal Atrophy, X-Linked 1Biliary Tract Neoplasms 1Adrenal Insufficiency 1

Interventions

Magnetic Resonance Spectroscopy 56enzalutamide 44Specimen Handling 37apalutamide 35Androgen Antagonists 35Abiraterone Acetate 29Prednisone 27Radiosurgery 26darolutamide 25Docetaxel 23Pluvicto 22abiraterone 21Radiotherapy 21Leuprolide 20Biopsy 16relugolix 14acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 14gallium 68 PSMA-11 12Triptorelin Pamoate 12Surveys and Questionnaires 12Radiation 12Gonadotropin-Releasing Hormone 12X-Rays 112-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 10cabazitaxel 9bicalutamide 9Standard of Care 9Nivolumab 9Goserelin 9Carboplatin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Prednisolone × 90 days × Clear all
NCT06925737 2026-05-22

MK-2400-001

Merck Sharp & Dohme LLC

Phase 3 Recruiting
1,440 enrolled
Genitourinary

Prostatic Neoplasms

NCT06952803 2026-05-19

EvoPAR-PR02

AstraZeneca

Phase 3 Recruiting
700 enrolled
Genitourinary

Prostatic Neoplasms

NCT06764485 2026-05-06

rechARge

Celgene

Phase 3 Recruiting
960 enrolled
Genitourinary

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT07005154 2026-05-01

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

Astellas Pharma Inc

Phase 2 Recruiting
218 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡